JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022—2023

Jonathan Duffy; Tanya R. Myers; Paige Marquez; Douglas Rouse; Hannah Brown; Bicheng Zhang; David K. Shay; Pedro L. Moro

doi:10.1097/olq.0000000000001978

April 17, 2024Sexually Transmitted Diseases

JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022—2023

View Full Paper

Ask AI

Bookmark

Share

Key Points

Vaccine safety surveillance for the JYNNEOS vaccine established active monitoring across two complementary systems during the nationwide 2022 mpox outbreak.
Two complementary systems, including the Vaccine Adverse Event Reporting System and v-safe, evaluated post-vaccination safety during the 2022 to 2023 response.
Supports ongoing vaccine safety surveillance by coordinating two reporting systems to protect people with higher potential for exposure to mpox.

Implication

Surveillance study reports JYNNEOS vaccine safety in individuals with potential mpox exposure, highlighting coordinated multi-system monitoring.

Abstract

In response to the 2022 mpox outbreak in the United States, people with higher potential for exposure to mpox were recommended to receive 2 doses of the JYNNEOS vaccine. Vaccine safety was monitored using 2 complementary systems.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Duffy et al. (2024) studied this question.

synapsesocial.com/papers/68e6eaccb6db643587665f12 https://doi.org/10.1097/olq.0000000000001978

View Full Paper

Ask AI

Bookmark

Share

JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022—2023

Key Points

Implication

Abstract

Discussion

Cite This Study

JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022—2023

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading